Pharmacogenomic update on multiple sclerosis: A focus on actual and new therapeutic strategies

Pharmacogenomics Journal

Volumn 12, Issue 6, 2012, Pages 453-461

  Cuzzola, V Foti ^a   Palella, E ^a   Celi, D ^a   Barresi, M ^a   Giacoppo, S ^a   Bramanti, P ^a   Marino, S ^a  

^a IRCCS CENTRO NEUROLESI BONINO PULEJO   (Italy)

Author keywords

glatiramer acetate; IFN b; IFNAR; multiple sclerosis; MxA; pharmacogenetics

Indexed keywords

BETA INTERFERON; BETA1A INTERFERON; BREAST CANCER RESISTANCE PROTEIN; CXCL9 CHEMOKINE; FINGOLIMOD; GAMMA INTERFERON; GAMMA INTERFERON INDUCIBLE PROTEIN 10; GLATIRAMER; INTERFERON BETA SERINE; INTERLEUKIN 1BETA; INTERLEUKIN 6; INTERLEUKIN 8; MITOXANTRONE; MONOCYTE CHEMOTACTIC PROTEIN 1; MULTIDRUG RESISTANCE PROTEIN 1; NATALIZUMAB; TUMOR NECROSIS FACTOR ALPHA;

ABCB1 GENE; ABCG2 GENE; ABCG2L GENE; B LYMPHOCYTE; B2M GENE; BLOOD BRAIN BARRIER; BRADYCARDIA; CARDIOTOXICITY; CASP10 GENE; CELL ACTIVATION; CHRONIC DRUG ADMINISTRATION; CLINICAL EFFECTIVENESS; CLINICAL PRACTICE; CYTOKINE RELEASE; DEGENERATIVE DISEASE; DEMYELINATING DISEASE; DEPRESSION; DRUG ABSORPTION; DRUG APPROVAL; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG EXCRETION; DRUG MECHANISM; DRUG TARGETING; DRUG TRANSPORT; ENZYME ACTIVATION; EVIDENCE BASED PRACTICE; EXPERIMENTAL THERAPY; FATIGUE; FLU LIKE SYNDROME; FOOD AND DRUG ADMINISTRATION; GENE EXPRESSION; GENETIC ASSOCIATION; GENETIC CORRELATION; GENETIC MARKER; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; HEALTH CARE DISPARITY; HERPES SIMPLEX; HUMAN; IFI44 GENE; IFIT1 GENE; IFIT2 GENE; IFIT3 GENE; IFITM1 GENE; IFNAR1 GENE; IFNAR2 GENE; IL6 GENE; IL8 GENE; IMMUNE RESPONSE; IMMUNOMODULATION; IMMUNOSUPPRESSIVE TREATMENT; IRF1 GENE; LEUKEMIA; LICENSING; LONG TERM CARE; MULTIPLE SCLEROSIS; MXA GENE; MYELINATED NERVE; NERVOUS SYSTEM INFLAMMATION; OASL GENE; PATIENT COMPLIANCE; PHARMACOGENOMICS; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; PROTEIN EXPRESSION; REVIEW; RISK BENEFIT ANALYSIS; SIGNAL TRANSDUCTION; STANDARDIZATION; STAT1 GENE; SYMPTOMATOLOGY; T LYMPHOCYTE; TGFB2 GENE; TREATMENT RESPONSE;

CATHEPSINS; GTP-BINDING PROTEINS; HUMANS; INTERFERON-BETA; MULTIPLE SCLEROSIS; PEPTIDES; PHARMACOGENETICS; RECEPTOR, INTERFERON ALPHA-BETA;

EID: 84870058818     PISSN: 1470269X     EISSN: 14731150     Source Type: Journal    
DOI: 10.1038/tpj.2012.41     Document Type: Review

References (80)

1. Borisow N, Doring A, Pfueller CF, Paul F, Dorr J, Hellwig K. Expert recommendations to personalization of medical approaches in treatment of multiple sclerosis: an overview of family planning and pregnancy. EPMA J 2012; 3: 9.
2. Rejdak K, Jackson S, Giovannoni G. Multiple sclerosis: a practical overview for clinicians. Br Med Bull 2010; 95: 79-104.
3. Galetta SL, Markowitz C, Lee AG. Immunomodulatory agents for the treatment of relapsing multiple sclerosis: a systematic review. Arch Intern Med 2002; 162: 2161-2169.
4. Polman CH, Reingold SC, Banwell B, Clanet M, Cohen JA, Filippi M et al. Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann Neurol 2011; 69: 292-302.
5. Trojano M, Liguori M, Paolicelli D, Zimatore GB, De Robertis F, Avolio C et al. Interferon beta in relapsing-remitting multiple sclerosis: an independent postmarketing study in southern Italy. Mult Scler 2003; 9: 451-457.
6. Castro-Borrero W, Graves D, Frohman TC, Flores AB, Hardeman P, Logan D et al. Current and emerging therapies in multiple sclerosis: a systematic review. Ther Adv Neurol Disord 2012; 5: 205-220.
7. Kleinschnitz C, Meuth SG, Kieseier BC, Wiendl H. Immunotherapeutic approaches in MS: update on pathophysiology and emerging agents or strategies 2006. Endocr Metab Immune Disord Drug Targets 2007; 7: 35-63.
8. Farrell RA, Giovannoni G. Current and future role of interferon beta in the therapy of multiple sclerosis. J Interferon Cytokine Res 2010; 30: 715-726.
9. Trapp BD, Peterson J, Ransohoff RM, Rudick R, Mork S, Bo L. Axonal transection in the lesions of multiple sclerosis. N Engl J Med 1998; 338: 278-285.
10. Leary SM, Miller DH, Stevenson VL, Brex PA, Chard DT, Thompson AJ. Interferon beta-1a in primary progressive MS: an exploratory, randomized, controlled trial. Neurology 2003; 60: 44-51.
11. Montalban X. Overview of European pilot study of interferon beta-Ib in primary progressive multiple sclerosis. Mult Scler 2004; 10(Suppl 1): S62; discussion 62-4.
12. Wolinsky JS. PROMiSe Trial Study Group. The PROMiSe trial: baseline data review and progress report. Mult Scler 2004; 10(Suppl 1): S65-S71; discussion S71-2.
13. Neilley LK, Goodin DS, Goodkin DE, Hauser SL. Side effect profile of interferon beta-1b in MS: results of an open label trial. Neurology 1996; 46: 552-554.
14. Borden EC, Sen GC, Uze G, Silverman RH, Ransohoff RM, Foster GR et al. Interferons at age 50: past, current and future impact on biomedicine. Nat Rev Drug Discov 2007; 6: 975-990.
15. Gasperini C, Ruggieri S. New oral drugs for multiple sclerosis. Neurol Sci 2009; 30(Suppl 2): S179-S183.
16. Neuhaus O, Kieseier BC, Hartung HP. Immunosuppressive agents in multiple sclerosis. Neurotherapeutics 2007; 4: 654-660.
17. Miller DH, Khan OA, Sheremata WA, Blumhardt LD, Rice GP, Libonati MA et al. A controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 2003; 348: 15-23.
18. Brassat D, Recher C, Waubant E, Le Page E, Rigal-Huguet F, Laurent G et al. Therapy-related acute myeloblastic leukemia after mitoxantrone treatment in a patient with MS. Neurology 2002; 59: 954-955.
19. Hartung HP, Aktas O. Oral therapies for multiple sclerosis: are we there yet? Lancet Neurol 2010; 9: 454-457.
20. Brinkmann V. FTY720 (fingolimod) in multiple sclerosis: therapeutic effects in the immune and the central nervous system. Br J Pharmacol 2009; 158: 1173-1182.
21. Weinstock-Guttman B, Badgett D, Patrick K, Hartrich L, Santos R, Hall D et al. Genomic effects of IFN-beta in multiple sclerosis patients. J Immunol 2003; 171: 2694-2702.
22. Taniguchi T, Takaoka A. The interferon-alpha/beta system in antiviral responses: a multimodal machinery of gene regulation by the IRF family of transcription factors. Curr Opin Immunol 2002; 14: 111-116.
23. Weinstock-Guttman B, Bhasi K, Badgett D, Tamano-Blanco M, Minhas M, Feichter J et al. Genomic effects of once-weekly, intramuscular interferon-beta1a treatment after the first dose and on chronic dosing: relationships to 5-year clinical outcomes in multiple sclerosis patients. J Neuroimmunol 2008; 205: 113-125.
24. Sturzebecher S, Wandinger KP, Rosenwald A, Sathyamoorthy M, Tzou A, Mattar P et al. Expression profiling identifies responder and non-responder phenotypes to interferon-beta in multiple sclerosis. Brain 2003; 126(Pt 6): 1419-1429.
25. Lindberg RL, Achtnichts L, Hoffmann F, Kuhle J, Kappos L. Natalizumab alters transcriptional expression profiles of blood cell subpopulations of multiple sclerosis patients. J Neuroimmunol 2008; 194: 153-164.
26. Comabella M, Craig DW, Morcillo-Suarez C, Rio J, Navarro A, Fernandez M et al. Genome-wide scan of 500 000 single-nucleotide polymorphisms among responders and nonresponders to interferon beta therapy in multiple sclerosis. Arch Neurol 2009; 66: 972-978.
27. Kochs G, Haller OGTP. bound human MxA protein interacts with the nucleocapsids of Thogoto virus (Orthomyxoviridae). J Biol Chem 1999; 274: 4370-4376.
28. Yu Z, Wang Z, Chen J, Li H, Lin Z, Zhang F et al. GTPase activity is not essential for the interferon-inducible MxA protein to inhibit the replication of hepatitis B virus. Arch Virol 2008; 153: 1677-1684.
29. Lampe JB, Schneider-Schaulies S, Aguzzi A. Expression of the interferon-induced MxA protein in viral encephalitis. Neuropathol Appl Neurobiol 2003; 29: 273-279.
30. Al-Masri AN, Heidenreich F, Walter GF. Interferon-induced Mx proteins in brain tissue of multiple sclerosis patients. Eur J Neurol 2009; 16: 721-726.
31. Pungor Jr E, Files JG, Gabe JD, Do LT, Foley WP, Gray JL et al. A novel bioassay for the determination of neutralizing antibodies to IFN-beta1b. J Interferon Cytokine Res 1998; 18: 1025-1030.
32. Kracke A, von Wussow P, Al-Masri AN, Dalley G, Windhagen A, Heidenreich F. Mx proteins in blood leukocytes for monitoring interferon beta-1b therapy in patients with MS. Neurology 2000; 54: 193-199.
33. Serrano-Fernandez P, Moller S, Goertsches R, Fiedler H, Koczan D, Thiesen HJ et al. Time course transcriptomics of IFNB1b drug therapy in multiple sclerosis. Autoimmunity 2010; 43: 172-178.
34. Hilpert J, Beekman JM, Schwenke S, Kowal K, Bauer D, Lampe J et al. Biological response genes after single dose administration of interferon beta-1b to healthy male volunteers. J Neuroimmunol 2008; 199: 115-125.
35. Sriram U, Barcellos LF, Villoslada P, Rio J, Baranzini SE, Caillier S et al. Pharmacogenomic analysis of interferon receptor polymorphisms in multiple sclerosis. Genes Immun 2003; 4: 147-152.
36. Cunningham S, Graham C, Hutchinson M, Droogan A, O'Rourke K, Patterson C et al. Pharmacogenomics of responsiveness to interferon IFN-beta treatment in multiple sclerosis: a genetic screen of 100 type I interferon-inducible genes. Clin Pharmacol Ther 2005; 78: 635-646.
37. Leyva L, Fernandez O, Fedetz M, Blanco E, Fernandez VE, Oliver B et al. IFNAR1 and IFNAR2 polymorphisms confer susceptibility to multiple sclerosis but not to interferon-beta treatment response. J Neuroimmunol 2005; 163: 165-171.
38. Oliver B, Mayorga C, Fernandez V, Leyva L, Leon A, Luque G et al. Interferon receptor expression in multiple sclerosis patients. J Neuroimmunol 2007; 183: 225-231.
39. Serana F, Sottini A, Ghidini C, Zanotti C, Capra R, Cordioli C et al. Modulation of IFNAR1 mRNA expression in multiple sclerosis patients. J Neuroimmunol 2008; 197: 54-62.
40. Byun E, Caillier SJ, Montalban X, Villoslada P, Fernandez O, Brassat D et al. Genome-wide pharmacogenomic analysis of the response to interferon beta therapy in multiple sclerosis. Arch Neurol 2008; 65: 337-344.
41. Filmus J, Capurro M, Rast J. Glypicans. Genome Biol 2008; 9: 224.
42. Van Vactor D, Wall DP, Johnson KG. Heparan sulfate proteoglycans and the emergence of neuronal connectivity. Curr Opin Neurobiol 2006; 16: 40-51.
43. Cenit MD, Blanco-Kelly F, de las Heras V, Bartolome M, de la Concha EG, Urcelay E et al. Glypican 5 is an interferon-beta response gene: a replication study. Mult Scler 2009; 15: 913-917.
44. Tsunoda T, Takashima Y, Tanaka Y, Fujimoto T, Doi K, Hirose Y et al. Immunerelated zinc finger gene ZFAT is an essential transcriptional regulator for hematopoietic differentiation in blood islands. Proc Natl Acad Sci USA 2010; 107: 14199-14204.
45. Hemmi K, Ma D, Miura Y, Kawaguchi M, Sasahara M, Hashimoto-Tamaoki T et al. A homeodomain-zinc finger protein, ZFHX4, is expressed in neuronal differentiation manner and suppressed in muscle differentiation manner. Biol Pharm Bull 2006; 29: 1830-1835.
46. Wergeland S, Beiske A, Nyland H, Hovdal H, Jensen D, Larsen JP et al. IL-10 promoter haplotype influence on interferon treatment response in multiple sclerosis. Eur J Neurol 2005; 12: 171-175.
47. Edwards-Smith CJ, Jonsson JR, Purdie DM, Bansal A, Shorthouse C, Powell EE. Interleukin-10 promoter polymorphism predicts initial response of chronic hepatitis C to interferon alfa. Hepatology 1999; 30: 526-530.
48. Goertsches RH, Hecker M, Koczan D, Serrano-Fernandez P, Moeller S, Thiesen HJ et al. Long-term genome-wide blood RNA expression profiles yield novel molecular response candidates for IFN-beta-1b treatment in relapsing remitting MS. Pharmacogenomics 2010; 11: 147-161.
49. Qin H, Wilson CA, Lee SJ, Benveniste EN. IFN-beta-induced SOCS-1 negatively regulates CD40 gene expression in macrophages and microglia. FASEB J 2006; 20: 985-987.
50. Guerrero AL, Tejero MA, Gutierrez F, Martin-Polo J, Iglesias F, Laherran E et al. Influence of APOE gene polymorphisms on interferon-beta treatment response in multiple sclerosis. Neurologia 2011; 26: 137-142.
51. Carmona O, Masuet C, Alia P, Moral E, Alonso-Magdalena L, Casado V et al. Apolipoprotein alleles and the response to interferon-beta-1b in multiple sclerosis. Eur Neurol 2011; 65: 132-137.
52. da Silva AJ, Brickelmaier M, Majeau GR, Lukashin AV, Peyman J, Whitty A et al. Comparison of gene expression patterns induced by treatment of human umbilical vein endothelial cells with IFN-alpha 2b vs. IFN-beta 1a: understanding the functional relationship between distinct type I interferons that act through a common receptor. J Interferon Cytokine Res 2002; 22: 173-188.
53. Der SD, Zhou A, Williams BR, Silverman RH. Identification of genes differentially regulated by interferon alpha, beta, or gamma using oligonucleotide arrays. Proc Natl Acad Sci USA 1998; 95: 15623-15628.
54. Paolicelli D, Direnzo V, Trojano M. Review of interferon beta-1b in the treatment of early and relapsing multiple sclerosis. Biologics 2009; 3: 369-376.
55. Rio J, Nos C, Tintore M, Tellez N, Galan I, Pelayo R et al. Defining the response to interferon-beta in relapsing-remitting multiple sclerosis patients. Ann Neurol 2006; 59: 344-352.
56. Waubant E, Vukusic S, Gignoux L, Dubief FD, Achiti I, Blanc S et al. Clinical characteristics of responders to interferon therapy for relapsing MS. Neurology 2003; 61: 184-189.
57. Enevold C, Oturai AB, Sorensen PS, Ryder LP, Koch-Henriksen N, Bendtzen K. Polymorphisms of innate pattern recognition receptors, response to interferonbeta and development of neutralizing antibodies in multiple sclerosis patients. Mult Scler 2010; 16: 942-949.
58. Wiesemann E, Deb M, Hemmer B, Radeke HH, Windhagen A. Early identification of interferon-beta responders by ex vivo testing in patients with multiple sclerosis. Clin Immunol 2008; 128: 306-313.
59. van Baarsen LG, Vosslamber S, Tijssen M, Baggen JM, van der Voort LF, Killestein J et al. Pharmacogenomics of interferon-beta therapy in multiple sclerosis: baseline IFN signature determines pharmacological differences between patients. PLoS One 2008; 3: e1927.
60. Rudick RA, Lee JC, Simon J, Ransohoff RM, Fisher E. Defining interferon beta response status in multiple sclerosis patients. Ann Neurol 2004; 56: 548-555.
61. Petzold A, Brassat D, Mas P, Rejdak K, Keir G, Giovannoni G et al. Treatment response in relation to inflammatory and axonal surrogate marker in multiple sclerosis. Mult Scler 2004; 10: 281-283.
62. Stone LA, Frank JA, Albert PS, Bash CN, Calabresi PA, Maloni H et al. Characterization of MRI response to treatment with interferon beta-1b: contrast-enhancing MRI lesion frequency as a primary outcome measure. Neurology 1997; 49: 862-869.
63. Macciardi F, Boneschi FM, Cohen D. Pharmacogenetics of autoimmune diseases: research issues in the case of multiple sclerosis and the role of IFN-beta. J Autoimmun 2005; 25(Suppl): 1-5.
64. Miller A, Shapiro S, Gershtein R, Kinarty A, Rawashdeh H, Honigman S et al. Treatment of multiple sclerosis with copolymer-1 (Copaxone): implicating mechanisms of Th1 to Th2/Th3 immune-deviation. J Neuroimmunol 1998; 92: 113-121.
65. Kim HJ, Ifergan I, Antel JP, Seguin R, Duddy M, Lapierre Y et al. Type 2 monocyte and microglia differentiation mediated by glatiramer acetate therapy in patients with multiple sclerosis. J Immunol 2004; 172: 7144-7153.
66. Blanchette F, Neuhaus O. Glatiramer acetate: evidence for a dual mechanism of action. J Neurol 2008; 255(Suppl 1): 26-36.
67. Fusco C, Andreone V, Coppola G, Luongo V, Guerini F, Pace E et al. HLADRB1* 1501 and response to copolymer-1 therapy in relapsing-remitting multiple sclerosis. Neurology 2001; 57: 1976-1979.
68. Nakanishi H. Microglial functions and proteases. Mol Neurobiol 2003; 27: 163-176.
69. Beck H, Schwarz G, Schroter CJ, Deeg M, Baier D, Stevanovic S et al. Cathepsin S and an asparagine-specific endoprotease dominate the proteolytic processing of human myelin basic protein in vitro. Eur J Immunol 2001; 31: 3726-3736.
70. Grossman I, Avidan N, Singer C, Goldstaub D, Hayardeny L, Eyal E et al. Pharmacogenetics of glatiramer acetate therapy for multiple sclerosis reveals drugresponse markers. Pharmacogenet Genomics 2007; 17: 657-666.
71. Pappas DJ, Oksenberg JR. Multiple sclerosis pharmacogenomics: maximizing efficacy of therapy. Neurology 2010; 74(Suppl 1): S62-S69.
72. Valenzuela RM, Costello K, Chen M, Said A, Johnson KP, Dhib-Jalbut S. Clinical response to glatiramer acetate correlates with modulation of IFN-gamma and IL-4 expression in multiple sclerosis. Mult Scler 2007; 13: 754-762.
73. Tsareva EY, Kulakova OG, Boyko AN, Shchur SG, Lvovs D, Favorov AV et al. Allelic combinations of immune-response genes associated with glatiramer acetate treatment response in Russian multiple sclerosis patients. Pharmacogenomics 2012; 13: 43-53.
74. Jones PM, George AM. The ABC transporter structure and mechanism: perspectives on recent research. Cell Mol Life Sci 2004; 61: 682-699.
75. Loscher W, Potschka H. Blood-brain barrier active efflux transporters: ATP-binding cassette gene family. NeuroRx 2005; 2: 86-98.
76. Cotte S, von Ahsen N, Kruse N, Huber B, Winkelmann A, Zettl UK et al. ABC-transporter gene-polymorphisms are potential pharmacogenetic markers for mitoxantrone response in multiple sclerosis. Brain 2009; 132(Pt 9): 2517-2530.
77. Millonig A, Hegen H, Di Pauli F, Ehling R, Gneiss C, Hoelzl M et al. Natalizumab treatment reduces endothelial activity in MS patients. J Neuroimmunol 2010; 227: 190-194.
78. Mellergard J, Edstrom M, Vrethem M, Ernerudh J, Dahle C. Natalizumab treatment in multiple sclerosis: marked decline of chemokines and cytokines in cerebrospinal fluid. Mult Scler 2010; 16: 208-217.
79. Khademi M, Bornsen L, Rafatnia F, Andersson M, Brundin L, Piehl F et al. The effects of natalizumab on inflammatory mediators in multiple sclerosis: prospects for treatment-sensitive biomarkers. Eur J Neurol 2009; 16: 528-536.
80. Mehling M, Lindberg R, Raulf F, Kuhle J, Hess C, Kappos L et al. Th17 central memory T cells are reduced by FTY720 in patients with multiple sclerosis. Neurology 2010; 75: 403-410.